Women, Intersectionality, Substance Use and HIV ( WISH)

项目总结/摘要 这个指导研究科学家发展奖（K 01）的目的是为候选人提供 过渡到一个独立的研究生涯所需的培训和专业知识，重点是交叉 优化艾滋病毒治疗和干预的方法。K 01拥有强大的职业发展计划 并仔细联系的研究策略。本K 01研究部分的总体目标是 研究交叉羞辱和歧视如何导致艾滋病毒治疗结果的不平等， 探讨复原力如何促进不同种族的艾滋病毒感染妇女参与艾滋病毒护理， 在美国（US）使用药物（WLHIV-WUD）。这些信息将为选择和系统化提供信息。 调整艾滋病毒相关的循证干预措施，以促进 WLHIV-WUD这将通过以下三个具体目标来实现：1）评估成见的影响 艾滋病毒治疗结果在吸毒和种族之间的交叉点上的不平等 2）系统地调整与艾滋病毒相关的EBI，以减轻 并培养复原力，以促进艾滋病毒护理工作 在加利福尼亚州旧金山弗朗西斯科的种族多样性WLHIV-WUD;和3）评估 在不同种族的妇女、艾滋病毒携带者和妇女、女童和青少年中采取适应性的交叉知情艾滋病毒护理参与干预措施， 加利福尼亚州旧金山弗朗西斯科。Jennifer Jain博士是进行这项研究的最佳人选，因为她有很强的 流行病学方法和艾滋病毒与药物使用研究知识基础。5年颁奖期间 在此期间，Jain博士将实现以下职业发展目标：1）获得内容专业知识， 交叉性理论和研究，重点是世界妇女、艾滋病毒/艾滋病联合会-妇女、女童和发展联合会之间的艾滋病毒护理参与， （2）发展先进统计技术方面的方法学专门知识，以实现量化交叉性， 混合方法; 3）获得干预科学的培训，包括证据的适应和检验- 基于干预措施的重点是美国WLHIV-WUD之间的艾滋病毒护理参与; 4）培养技能， 成功的独立研究生涯，包括granitary，科学手稿写作和 跨学科合作研究。这将通过完成一系列不同的 培训活动包括导师指导学习、正式课程、研讨会和现实世界研究 体验.拟议的研究与目前NIH的优先事项高度一致：1）进行艾滋病毒相关的 交叉污名研究; 2）改善吸毒者艾滋病毒感染者的健康状况;以及 3)加速艾滋病毒/艾滋病和药物使用研究方面的科学发现。此外，这项研究支持 博士Jain追求独立的研究生涯，专注于交叉方法，以提高艾滋病毒 治疗和干预种族多样的WLHIV-WUD在美国。

PROJECT SUMMARY/ABSTRACT The purpose of this Mentored Research Scientist Development Award (K01) is to provide the candidate with the training and expertise needed to transition into an independent research career focused on intersectional approaches to optimize HIV treatment and intervention. This K01 features a robust career development plan and carefully linked research strategy. The overall objective of the research component of this K01 is to examine how intersectional stigma and discrimination lead to inequalities in HIV treatment outcomes and explore how resilience promotes engagement in HIV care among racially diverse women living with HIV who use drugs (WLHIV-WUD) in the United States (US). This information will inform the selection and systematic adaptation of an HIV-related evidence-based intervention (EBI) to facilitate engagement in care among WLHIV-WUD. This will be achieved through the following three specific aims: 1) to assess the impact of stigma and discrimination on inequalities in HIV treatment outcomes across intersections of drug use and race among racially diverse WLHIV in the US; 2) to systematically adapt an HIV-related EBI to mitigate the impact of intersectional stigma and discrimination and cultivate resilience to facilitate HIV care engagement among racially diverse WLHIV-WUD in San Francisco, CA; and 3) to evaluate the acceptability and feasibility of the adapted intersectionality-informed HIV care engagement intervention among racially diverse WLHIV-WUD in San Francisco, CA. Dr. Jennifer Jain is the perfect candidate to conduct this research because of her strong knowledge base in epidemiological methods and HIV and substance use research. During the 5-year award period, Dr. Jain will achieve the following career development objectives: 1) gain content expertise in intersectionality theory and research with an emphasis on HIV care engagement among WLHIV-WUD in the US; 2) develop methodological expertise in advanced statistical techniques for quantitative intersectionality and mixed methods; 3) acquire training in intervention science, including the adaptation and testing of evidence- based interventions focused on HIV care engagement among WLHIV-WUD in the US; 4) build skills for a successful independent research career, including grantsmanship, scientific manuscript writing and collaborative cross-disciplinary research. This will be attained through the completion of a diverse set of training activities including mentor-directed learning, formal course work, seminars, and real-world research experience. The proposed research is highly consistent with current NIH priorities to: 1) conduct HIV-related intersectional stigma research; 2) improve health outcomes among people living with HIV who use drugs; and 3) accelerate scientific discoveries in HIV/AIDS and substance use research. Moreover, this research supports Dr. Jain’s pursuit of an independent career in research focused on intersectional approaches to enhance HIV treatment and intervention among racially diverse WLHIV-WUD in the US.